<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062917</url>
  </required_header>
  <id_info>
    <org_study_id>15/WM/0343</org_study_id>
    <nct_id>NCT03062917</nct_id>
  </id_info>
  <brief_title>Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis</brief_title>
  <acronym>RSV-SAM</acronym>
  <official_title>Validation of Nasal and Bronchial Absorption Sampling Methods for the Assessment of RSV Bronchiolitis in Babies and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pulmocide Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the novel methods of NS and BS with the standard technique of
      nasophayngeal aspiration (NPA) and routine ETT suction. We shall assess the samples for
      diagnosis of RSV, viral load and immune responses in the airways of babies with RSV
      infection. We shall also assess the genetics of babies included in this study, to see if they
      may be vulnerable to RSV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In conjunction with a specialist medical device manufacturing company (Hunt Developments
      (Midhurst, West Sussex) we have produced novel nasosorption and bronchosorption kits that
      have CE marking. Both nasosorption and bronchosorption methods use synthetic absorptive
      matrix (SAM) strips: that look and feel like blotting paper, and will be placed onto the
      mucosal surface. These are comfortable to use and can be used at frequent intervals over
      extended periods of time. This non-invasive technique is ideal for infants and children, and
      it is possible to obtain neat mucosal lining fluid (MLF) even from normal healthy noses. The
      eluates contain cytokines and chemokines at high detectable levels on multiplex immunoassay.

      We would like to use these SAMs to take MLF samples from the nasal and bronchial mucosal
      surfaces to see if these novel techniques can overcome the problems with current sampling
      methods. We plan to use these absorption techniques to measure RSV viral load. We also aim to
      look at the immune response in terms of the anti-viral interferon response (IFN-γ, IFN-λ,
      IFN-α2a, IP10, ITAC). In therapeutic studies in the future, it may be possible to document
      levels of drug (pharmacokinetics) in nasal MLF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2015</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling</measure>
    <time_frame>Throughout symptomatic respiratory infection, up to 1 month</time_frame>
    <description>To determine the difference in tolerability of nasosorption compared to NPA by assessment of acceptance by infants and families. Samples were collected from participants up to twice daily throughout study involvement, as such each participant could have &gt;1 sampling visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy of Nasosorption for Viral Load Measurement</measure>
    <time_frame>Throughout symptomatic respiratory infection, up to 1 month</time_frame>
    <description>To determine the difference in accuracy of nasosorption compared to NPA by assessment of level of viral load (measured by qPCR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy of Bronchosorption for Viral Load Measurement, Compared to Tracheal Aspirate</measure>
    <time_frame>Throughout symptomatic respiratory infection, up to 1 month</time_frame>
    <description>To determine the difference in accuracy of bronchosorption (BSAM) compared to tracheal aspirate (TA) by assessment of level of viral load (measured by qPCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Throughout symptomatic respiratory infection, up to 1 month</time_frame>
    <description>Establishing the use of nasal and bronchial sampling to measure the host immune response to RSV. We will determine cytokine and inflammatory mediator concentrations by immunoassay of eluted fluid from nasosorption and compare with NPA.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Bronchiolitis</condition>
  <condition>Bronchiolitis, Viral</condition>
  <condition>RSV Infection</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Emergency Department</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Babies with suspected respiratory tract infection (RTI) in the ED</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paediatric Wards</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Babies with diagnosed RSV infection admitted to paediatric wards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paediatric Intensive Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls in Paediatric Intensive Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Babies without RSV infection but requiring mechanical ventilation in PICU</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasal and Bronchial Sampling</intervention_name>
    <description>Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
    <arm_group_label>Controls in Paediatric Intensive Care</arm_group_label>
    <arm_group_label>Emergency Department</arm_group_label>
    <arm_group_label>Health Controls</arm_group_label>
    <arm_group_label>Paediatric Intensive Care</arm_group_label>
    <arm_group_label>Paediatric Wards</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1 and Group 2

        Inclusion Criteria

          -  Infants aged 2 weeks-24 months

          -  Presentation to the Emergency Department with any upper respiratory tract infection
             (URTI) in the RSV season (Oct-March).

        OR • Documented RSV infection, admitted to the paediatric wards at St Mary's Hospital.

        Exclusion Criteria

          -  Any local or systemic factor that would influence the safety of nasal sampling.

          -  Bilateral indwelling nasal catheters or local nasal pathology preventing access for
             nasal sampling.

          -  Bleeding disorders.

          -  The baby is taking part in another interventional study.

          -  The parents or guardians not able to sign the informed consent from due to limited
             English or comprehension despite the use of independent interpreter services.

          -  Limited life expectancy of the baby,

        Group 3

        Inclusion criteria

          -  Hospitalised Infants admitted to the PICU at St. Mary's Hospital, aged 2 weeks-24
             months with documented RSV infection (by rapid test and/or PCR).

          -  Infants of weight &gt;2kg.

          -  On a conventional ventilator with an Endotracheal Tube (ETT) of &gt;3.0mmm diameter

        Exclusion criteria

          -  Any local or systemic factor that would influence the safety of nasal sampling.

          -  Bilateral nasal catheters or local nasal pathology preventing access for nasal
             sampling.

          -  The baby is taking part in another interventional study.

          -  Prematurity - corrected gestational age &lt;36 weeks, weight &lt;2kg

          -  Significant hypoxia or instability precluding ventilator disconnection

          -  ETT &lt; 3mm internal diameter

          -  Transcutaneous oxygen saturation of &lt;95% on 60% oxygen

          -  Risk of bleeding

          -  Pneumothorax

          -  Infants receiving oral corticosteroid therapy at any time in past month

          -  Parents or guardians not able to sign informed consent from due to limited English or
             understanding despite the use of independent interpreter services.

          -  Limited life expectancy or a decision to limit management,

        Control Group 1 Inclusion criteria

        • Babies, aged 2 weeks-24 months, attending routine outpatient appointments or undergoing
        elective surgical procedures.

        Exclusion criteria

          -  Any respiratory symptoms

          -  All other exclusion are the same as Groups 1 and 2

        Control Group 2

        Inclusion criteria

          -  Infants aged 2 weeks-24 months.

          -  Infants ventilated on the PICU for any condition

          -  Confirmed RSV negative by PCR of respiratory tract samples

        Exclusion Criteria

          -  All exclusions are the same as Group 3

          -  In addition - any concern about raised intracranial pressure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Imperial College NHS Healthcare Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <results_first_submitted>August 14, 2019</results_first_submitted>
  <results_first_submitted_qc>October 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2019</results_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Bronchiolitis, Viral</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Participants consented that blood or nasal samples taken during this study can be used in the future for any ethically-approved studies.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03062917/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Emergency Department</title>
          <description>Babies with suspected respiratory tract infection (RTI) in the ED
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="P2">
          <title>Paediatric Wards</title>
          <description>Babies with diagnosed RSV infection admitted to paediatric wards
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="P3">
          <title>Paediatric Intensive Care</title>
          <description>Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="P4">
          <title>Health Controls</title>
          <description>Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="P5">
          <title>Controls in Paediatric Intensive Care</title>
          <description>Babies without RSV infection but requiring mechanical ventilation in PICU
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Controls in paediatric intensive care were sought but non recruited</population>
      <group_list>
        <group group_id="B1">
          <title>Emergency Department</title>
          <description>Babies with suspected respiratory tract infection (RTI) in the ED
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="B2">
          <title>Paediatric Wards</title>
          <description>Babies with diagnosed RSV infection admitted to paediatric wards
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="B3">
          <title>Paediatric Intensive Care</title>
          <description>Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="B4">
          <title>Health Controls</title>
          <description>Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="B5">
          <title>Controls in Paediatric Intensive Care</title>
          <description>Babies without RSV infection but requiring mechanical ventilation in PICU
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212" lower_limit="27" upper_limit="630"/>
                    <measurement group_id="B2" value="186" lower_limit="23" upper_limit="571"/>
                    <measurement group_id="B3" value="168" lower_limit="14" upper_limit="630"/>
                    <measurement group_id="B4" value="168" lower_limit="33" upper_limit="313"/>
                    <measurement group_id="B6" value="176" lower_limit="14" upper_limit="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B6" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B6" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B6" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling</title>
        <description>To determine the difference in tolerability of nasosorption compared to NPA by assessment of acceptance by infants and families. Samples were collected from participants up to twice daily throughout study involvement, as such each participant could have &gt;1 sampling visits.</description>
        <time_frame>Throughout symptomatic respiratory infection, up to 1 month</time_frame>
        <population>Parents asked at each sampling timepoint on willingness to continue with respiratory sampling, as either: 1) both nasosorption and NPA, 2) just nasosorption, 3) just NPA, 4) discontinue sampling. This analysis includes all non-sedated hospitalised participants as sedation would influence the tolerability of sampling as perceived by parents/carers.</population>
        <group_list>
          <group group_id="O1">
            <title>Wards</title>
            <description>None sedated participants recruited from general paediatric wards</description>
          </group>
          <group group_id="O2">
            <title>Emergency Department</title>
            <description>Non-ventilated participants recruited from the emergency department</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling</title>
          <description>To determine the difference in tolerability of nasosorption compared to NPA by assessment of acceptance by infants and families. Samples were collected from participants up to twice daily throughout study involvement, as such each participant could have &gt;1 sampling visits.</description>
          <population>Parents asked at each sampling timepoint on willingness to continue with respiratory sampling, as either: 1) both nasosorption and NPA, 2) just nasosorption, 3) just NPA, 4) discontinue sampling. This analysis includes all non-sedated hospitalised participants as sedation would influence the tolerability of sampling as perceived by parents/carers.</population>
          <units>Sampling visits</units>
          <param>Number</param>
          <units_analyzed>Number of individual sampling visits</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of individual sampling visits</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasosorption and NPA samples</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NPA only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinue sampling (while remaining in hospital)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasosorption only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accuracy of Nasosorption for Viral Load Measurement</title>
        <description>To determine the difference in accuracy of nasosorption compared to NPA by assessment of level of viral load (measured by qPCR).</description>
        <time_frame>Throughout symptomatic respiratory infection, up to 1 month</time_frame>
        <population>Spearman R score correlation between RSV viral load as measured by nasosorption and NPA. This analysis includes all RSV+ infants independent of recruitment group as no differences in correlation between sample type were anticipated between recruitment group.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Correlation between measurements of viral load and cytokines between nasosorption and NPA samples</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy of Nasosorption for Viral Load Measurement</title>
          <description>To determine the difference in accuracy of nasosorption compared to NPA by assessment of level of viral load (measured by qPCR).</description>
          <population>Spearman R score correlation between RSV viral load as measured by nasosorption and NPA. This analysis includes all RSV+ infants independent of recruitment group as no differences in correlation between sample type were anticipated between recruitment group.</population>
          <units>Spearman R score</units>
          <param>Number</param>
          <units_analyzed>Number matched RSV+ nasosorption and NPA</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number matched RSV+ nasosorption and NPA</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <description>Establishing the use of nasal and bronchial sampling to measure the host immune response to RSV. We will determine cytokine and inflammatory mediator concentrations by immunoassay of eluted fluid from nasosorption and compare with NPA.</description>
        <time_frame>Throughout symptomatic respiratory infection, up to 1 month</time_frame>
        <population>Spearman R score correlation of Interferon-gamma levels in matched nasosorption and NPA samples from any participant. This analysis includes all RSV+ infants independent of recruitment group as no differences in correlation between sample type were anticipated between recruitment group.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Correlation between measurements of cytokines (exemplified by Interferon-gamma) between nasosorption and NPA samples</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <description>Establishing the use of nasal and bronchial sampling to measure the host immune response to RSV. We will determine cytokine and inflammatory mediator concentrations by immunoassay of eluted fluid from nasosorption and compare with NPA.</description>
          <population>Spearman R score correlation of Interferon-gamma levels in matched nasosorption and NPA samples from any participant. This analysis includes all RSV+ infants independent of recruitment group as no differences in correlation between sample type were anticipated between recruitment group.</population>
          <units>Spearman R score</units>
          <param>Number</param>
          <units_analyzed>Number matched nasosorption and NPA</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number matched nasosorption and NPA</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accuracy of Bronchosorption for Viral Load Measurement, Compared to Tracheal Aspirate</title>
        <description>To determine the difference in accuracy of bronchosorption (BSAM) compared to tracheal aspirate (TA) by assessment of level of viral load (measured by qPCR).</description>
        <time_frame>Throughout symptomatic respiratory infection, up to 1 month</time_frame>
        <population>Spearman R score correlation between RSV viral load as measured by bronchosorption and tracheal aspiration. This analysis includes all RSV+ infants independent of recruitment group as no differences in correlation between sample type were anticipated between recruitment group.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Correlation between measurements of viral load and cytokines between nasosorption and NPA samples</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy of Bronchosorption for Viral Load Measurement, Compared to Tracheal Aspirate</title>
          <description>To determine the difference in accuracy of bronchosorption (BSAM) compared to tracheal aspirate (TA) by assessment of level of viral load (measured by qPCR).</description>
          <population>Spearman R score correlation between RSV viral load as measured by bronchosorption and tracheal aspiration. This analysis includes all RSV+ infants independent of recruitment group as no differences in correlation between sample type were anticipated between recruitment group.</population>
          <units>Spearman R score</units>
          <param>Number</param>
          <units_analyzed>Number matched RSV+ BSAM and TA</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number matched RSV+ BSAM and TA</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout participant hospitalisation, to a maximum of 6 months after the end of sampling</time_frame>
      <desc>As per clinicaltrials.gov definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Emergency Department</title>
          <description>Babies with suspected respiratory tract infection (RTI) in the ED
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="E2">
          <title>Paediatric Wards</title>
          <description>Babies with diagnosed RSV infection admitted to paediatric wards
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="E3">
          <title>Paediatric Intensive Care</title>
          <description>Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="E4">
          <title>Health Controls</title>
          <description>Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
        <group group_id="E5">
          <title>Controls in Paediatric Intensive Care</title>
          <description>Babies without RSV infection but requiring mechanical ventilation in PICU
Nasal and Bronchial Sampling: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study PI Simon Nadel</name_or_title>
      <organization>Imperial College NHS trust</organization>
      <phone>02033126202</phone>
      <email>s.nadel@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

